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Gold nanoparticle interactions with endothelial cells cultured 
under physiological conditions 
C. Freesea*, L. Anspacha, R. C. Dellerb†, S.-J. Richardsb, M. I. Gibsonb, C. J. Kirkpatricka and R. E. 
Ungera 
PEGylated gold nanoparticles (AuNPs) have an extended circulation time after intravenous injection in vivo and exhibit 
favorable properties for biosensing, diagnostic imaging, and cancer treatment. No impact of PEGylated AuNPs on the 
barrier forming properties of endothelial cells (ECs) has been reported, but recent studies demonstrated that unexpected 
effects on erythrocytes are observed. Almost all studies to date have been with static-cultured ECs. Herein, ECs maintained 
under physiological cyclic stretch and flow conditions and used to generate a blood-brain barrier model were exposed to 
20 nm PEGylated AuNPs. An evaluation of toxic effects, cell stress, the release profile of pro-inflammatory cytokines, and 
blood-brain barrier properties showed that even under physiological conditions no obvious effects of PEGylated AuNPs on 
ECs were observed. These findings suggest that 20 nm-sized, PEGylated AuNPs may be a useful tool for biomedical 
applications, as they do not affect the normal function of healthy ECs after entering the blood stream.
Introduction 
Specific physico-chemical properties make inorganic 
nanoparticles such as gold nanoparticles (AuNP) versatile tools 
for biomedical applications, which include biosensing, 
diagnostic imaging and cancer treatment.1,2 The inert 
character of gold, the easy and reproducible synthesis as well 
as the ease of functionalization with thiol-coating ligands make 
this desirable for a variety of applications. A number of studies 
with AuNPs have shown that size, shape, concentration, and 
surface modification of the NPs affect the interaction with cells 
and may lead to varying degrees of internalization and 
cytotoxicity.3–6 Modifying the surface of AuNPs with 
polyethylene glycol (PEG) has been demonstrated to prolong 
the circulation time in vivo,7,8 this being explained by a 
reduced renal filtration9 In addition, it has been demonstrated 
that 15 nm PEGylated AuNPs do not affect platelet 
aggregation, nor do they induce pro-inflammatory cytokines in 
endothelial cells.10 In previous studies it was also shown that 
PEGylated AuNPs of different sizes did not reduce cell viability 
or induce cellular stress and were internalized in low amounts 
by various microvascular endothelial cells compared to the 
same AuNPs functionalized with various surface polymers.6,11 
However, some studies have shown that AuNPs covered with 
PEG have a negative impact on cells and organisms. As 
demonstrated by Huang and colleagues 6.1 nm-sized 
PEGylated AuNPs were able to induce apoptosis of human 
chronic myeloid leukemia K562 cells.12 In addition to these in 
vitro results Cho et al. showed that treatment with 13 nm 
PEGylated AuNPs led to apoptotic effects in the liver of mice.13 
Furthermore, He et al. also showed that PEGylated AuNPs had 
a negative impact on the function of human erythrocytes.14 
Based on these contradictory results of the effects of 
PEGylated AuNPs on cells and organs we decided to use more 
biologically relevant in vitro culture conditions to analyse the 
effect of PEGylated AuNPs on ECs in vitro. 
The endothelium plays a pivotal role in the homeostasis of 
tissues and small changes in the function of ECs might impact 
the functionality of organs or even the health of an entire 
organism.15 In addition to examining toxic effects, an 
evaluation of PEGylated AuNPs on EC pro-inflammatory 
induction is necessary. An increased expression of cell 
adhesion molecules leads to leukocyte adhesion to the 
activated endothelium and results in transmigration into the 
tissue. To evaluate these parameters, three different model 
systems that differ from the traditional monocultures on tissue 
culture plastic were used. Since blood flow has been 
demonstrated to be important for endothelial differentiation 
and function,16–18 ECs were cultured under flow conditions and 
the morphology and cellular functions of ECs after the 
treatment with PEGylated AuNP were compared to cells grown 
under static conditions. In addition to flow, the impact of 
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stretch, which is also an important stimulus for EC function, 
was evaluated to determine how nanoparticles interact and 
influence cells under these conditions. We have previously 
shown that silica NPs interact differently with ECs under 
stretch compared to static culture conditions.19 The present 
study aims at determining if a changed nanoparticle-cell 
interaction is observed by comparing static to flow or stretch 
culture conditions and whether these conditions result in 
changes to the induction of cytotoxicity or pro-inflammatory 
effects in the presence of PEGylated AuNPs or whether the 
uptake behaviour of the NPs into cells is altered. The third 
model system is based on an in vitro blood-brain barrier (BBB) 
co-culture model previously described.20,21 Since the brain is 
protected by a specific differentiated endothelium that in 
concert with other cell types generates the neurovascular unit 
and protects the brain from xenobiotic substances,22,23 this 
model was used to determine if the synthesized PEGylated 
AuNPs impact the BBB. Thus, the integrity, the metabolic 
activity and the induction of cytokine expression of brain 
endothelial cells were also examined. Moreover, the transport 
properties across the barrier were determined using 
inductively coupled plasma and optical emission spectroscopy 
(ICP-OES). Due to the many promising biomedical applications 
of PEGylated AuNPs and to confirm the inert character of 
PEGylated AuNPs, this in vitro study was performed to 
investigate the impact of 20 nm PEGylated AuNPs on primary 
ECs by using more biologically relevant cell culture models and 
conditions. 
 
Experimental 
Nanoparticle synthesis and characterization 
Gold(III) chloride trihydrate (HAuCl4; > 49 % Au, ACS grade) and 
poly(ethylene glycol) 2-mercaptoethyl ether acetic acid (Mn = 
3500 g.mol-1) were purchased from Sigma-Aldrich. Tri-sodium 
citrate (99.8 %) was purchased from Acros Organics. Ultrahigh 
quality water with a resistance of 18.2 MΩ x cm (at 25°C) was 
obtained from a Millipore Milli-Q gradient machine fitted with 
a 0.22 μm filter. 20 nm PEGylated gold nanoparticles were 
synthesized as followed. First, 600 mL of a 0.85 mmol / L 
(0.33 mg / mL) aqueous solution of HAuCl4 was heated to 
reflux in a scratch-free round bottomed flask. After that, 
10.5 mL of a 0.5 mol / L aqueous solution of sodium citrate 
was added to the HAuCl4 solution to give an Au : citrate ratio 
of 1 : 3.5. The temperature was maintained at reflux for 30 
minutes, during which time a deep red coloration formed. The 
reaction mixture was then allowed to cool to room 
temperature over a period of 3 hours. AuNP PEGylation was 
performed by the addition of 5 mg 3.5 kDa poly(ethylene 
glycol) 2-mercaptoethyl ether acetic acid to 20 mL of 1 OD 
AuNPs for a period of 2 hours at room temperature prior to 
washing four times with milli-Q water by centrifugation at 
16000 x g for 15 minutes at room temperature. On the final 
wash the resulting supernatant was discarded and replaced 
with 5 mL of 100 mM MES buffer (pH 5). Particle size analysis 
was determined by dynamic light scattering using a Malvern 
Zetasizer Nano ZS instrument. A 4 mW He-Ne 633 nm laser 
module was used and scattered light was measured at 173° 
(back scattering). The attenuator and position was selected 
automatically by the instrument and particle sizes reported as 
the average of 4 measurements. UV-visible spectra were 
obtained using a Biotech Synergy HT and processed using the 
Gen5 software package. 
Isolation of HUVECs and assessment of cytotoxicity 
Umbilical cords were obtained from randomly selected healthy 
mothers. Human umbilical vein endothelial cells (HUVEC) were 
isolated according to a previously published method24 and 
cultured on gelatin-coated culture flasks using endothelial cell 
basal medium (ECBM; PromoCell), 15 % fetal calf serum, 
2.5 ng / mL basal fibroblast growth factor, 10 μg / mL sodium 
heparin (all Sigma-Aldrich) and 100 U  penicillin and 
100 mg / mL streptomycin (hereinafter referred to as ECBM 
culture medium) and used until passage 3. For experiments 
cells were seeded onto fibronectin-coated 96-well plates in 
ECBM culture medium and cultured to confluence. Cells were 
exposed to various concentrations of AuNPs for various time 
points. The AuNPs were diluted in ECBM, supplement mix 
(PromoCell) and 100 U penicillin and 100 mg / mL 
streptomycin (hereinafter referred to ECBM stimulation 
medium). Cell viability was measured using the CellTiter 96 
AQueous non-radioactive assay (Promega) as recommended 
by the manufacturer. For the detection of cytotoxicity caused 
by the treatment of AuNPs, 50 μL of the cell supernatant was 
used to carry out the CytoTox 96 non-radioactive cytotoxicity 
assay (Promega). As a positive control cells were lysed with 
1 % TritonX 100 (Sigma-Aldrich) in ECBM and set as 100 % LDH 
release. Control cells which have been treated with the 
appropriate volume of nanoparticle diluent were used to 
determine the basal level of LDH release. After measuring cell 
viability cells were washed with phosphate-buffered saline 
(PBS) and fixed with methanol / ethanol (2:1 (v / v)) at room 
temperature for 15 minutes and used for crystal violet staining 
or E-selectin determination by cell adhesion molecule enzyme 
immunoassay (CAM-EIA). Cells were incubated with 100 µL 
0.1 % crystal violet solution at room temperature for 20 
minutes. Afterwards excess of crystal violet was removed by 
washing the cells with water. The culture plates were dried 
and the bound crystal violet was dissolved by adding 60 µL 
acetic acid. The absorbance of the solution was measured at a 
wavelength of 600 nm using a multiplate reader (TECAN). E-
selectin CAM-EIA was performed as previously described to 
evaluate AuNPs as an initial screen for presence of 
endotoxin.25 Cells treated with 1 µg / mL lipopolysaccharide 
(LPS) was used as positive control and set as 100 % E-selectin 
expression. 
Uptake of AuNPs into primary endothelial cells 
HUVECs were seeded onto fibronectin-coated µ-slides (Ibidi) 
and cultured in ECBM culture medium until confluence. Cells 
were treated with 25 µg / mL AuNP in ECBM stimulation 
medium for 24 hours, washed, fixed with paraformaldehyde 
and stained with anti-CD31 antibody (DakoCytomation) as 
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described previously.26 Images were collected using a 
fluorescent microscope (Olympus IX71 with Delta Vision 
system, Applied Precision, USA). 
Nanoparticle treatment during cyclic stretch 
HUVECs were cultured on fibronectin-coated flexible silicon 
membranes (BioFlex Culture Plate (FlexCell International 
Corporation)) with ECBM culture medium and exposed to 
cyclic stretch (5 % elongation (sinus), 1 Hz) using a FX-4000 
Tension Plus FlexerCell strain unit and a FlexLink controller as 
described previously.19 After 24 hours of PEGylated AuNP 
treatment (25 µg / mL) supernatants were collected for ELISA 
and cells were fixed and stained as describe above. For 
quantification, cells were washed twice with PBS and collected 
in tubes after detachment with trypsin/EDTA (Gibco) solution. 
Nanoparticle treatment under flow condition 
HUVECs were seeded onto fibronectin-coated µ-Slide VI 0.1 
flow chambers (Ibidi) and cultured in ECBM culture medium. 
After 24 hours cell culture medium was changed to remove 
detached cells. The flow chamber was connected to the pump 
system consisting of the ibidi pump, the fluidic unit and 
controlled by the computer pump system. Shear stress was 
progressively increased up to 15 dyn / cm² starting with 7, to 9, 
to 11 dyn / cm² for 6 hours each. After 48 hours of flow the 
cells were incubated with PEGylated AuNPs for 24 hours under 
flow conditions using 25 µg / mL PEGylated AuNPs diluted in 
ECBM stimulation medium. The medium of the static controls 
was changed every day and stimulated with the same 
nanoparticle stock solution for 24 hours under static culture 
conditions. 
In vitro blood-brain barrier model 
Porcine brain endothelial cells (PBEC) were isolated and co-
cultured with SH-SY5Y cells as described previously.20,21 At day 
8 after seeding of PBECs, SH-SY5Y cells were seeded in the 
wells below the PBECs. After 24 hours of co-cultivation with 
SH-SY5Y cells, PBECs were treated with 12.5 and 25 µg / mL 
PEGylated AuNPs. For the treatment 20 µL of the supernatant 
was removed and 20 µL of PEGylated AuNPs and sodium 
fluorescein (NaFITC) was added. The transendothelial electrical 
resistance (TEER) was measured before and after 24 hours of 
nanoparticle exposure. In addition 50 µL of the supernatant 
from the lower compartment was transferred to a 96 well 
plate and fluorescence was measured (Ex 485 nm, Em 525 nm) 
to calculate the permeability coefficient of NaFITC as described 
previously.20 The medium above the cells was collected and 
used for the analysis of secreted IL-8 using the porcine ELISA 
(DuoSet, R&D Systems). For the determination of cell viability 
PBECs were washed with PBS and incubated with diluted MTS 
reagent (CellTiter 96 AQueous non-radioactive assay; 
Promega). After an incubation of 1 hour the absorbance was 
measured at 492 nm. For the staining procedure cells were 
washed with PBS and fixed with EtOH / MetOH (1:2 (v / v)) at 
room temperature for 20 minutes. Claudin-5 was stained as 
described previously using anti-claudin-5 (abcam).20 
Fluorescent images were collected using the fluorescent 
microscope BZ9000 (Keyence). For quantification of 
internalized PEGylated AuNPs PBECs were washed with PBS 
and collected after trypsination. In addition to the PBECs, the 
supernatant below the PBECs were analysed for the amount of 
transported PEGylated AuNPs across the in vitro BBB model 
system (see ICP-OES). 
Enzyme- linked immunosorbent assay (ELISA) 
After exposure to the PEGylated AuNPs under different culture 
conditions the supernatants of the cells were diluted in the 
appropriate assay diluent and analysed via ELISA (DuoSet, R&D 
Systems) for secreted soluble pro-inflammatory mediators 
(sVCAM, IL-8, MCP-1) as recommended by the manufacturer. 
To analyse the supernatant of the PBEC for IL-8 secretion the 
porcine IL-8 ELISA was used (DuoSet, R&D Systems). 
Inductively coupled plasma optical emission spectroscopy (ICP-
OES) 
To quantify the amount of gold within cells or in supernatants 
samples were prepared as described previously.27 Briefly, 
samples of 200 µL were treated with 150 µL of aqua regia (3:1 
hydrochloric acid : nitric acid (both purchased from Fisher 
Scientific)) at room temperature overnight. All samples were 
further diluted with 5 mL using MilliQ water to give a total 
sample volume of 5.35 mL. These samples were then analysed 
for total gold content by inductively coupled plasma optical 
emission spectroscopy (ICP-OES; Perkin Elmer Optima 
5300DV), and the measurement was repeated 3 times at a 
wavelength of 267.6 nm for each sample. 
Determination of RNA quality and Real-time Polymerase chain 
reaction (PCR) 
Cells were lysed with RLT buffer containing 1 % β-
mercaptoethanol. RNA was isolated using RNeasy Midi Kit 
(Qiagen) as described by the manufacturer. The amount of 
RNA in each sample was measured with the NanoDrop 
ND1000 spectrophotometer. To investigate the quality of the 
RNA the RNA integrity number (RIN) was determined by using 
Agilent Bioanalyzer and Agilent RNA 6000 Pico Kit. RNA with a 
RIN ≥ 9.7 was used for quantitative real-time PCR. 1 µg of RNA 
was used for the reverse transcription polymerase chain 
reaction according to a standard protocol using Omniscript RT 
kit (Qiagen). For the quantitative real-time PCR 4 ng cDNA was 
amplified using 12.5 μL of Power SYBR® Green PCR Master Mix 
(Applied Biosystems) and 100 nM of each primer in each 
reaction. Quantitative real-time PCR was performed in 
triplicate with the 7300 Real-time PCR System (Applied 
Biosystems) using the following cycler program: 95°C, 15 min; 
denaturation step: 94°C; 15 s; annealing step: 60°C 30 s; 
elongation step: 72°C 35 s; dissociation: 95°C 15 s; 60°C 1 min; 
95°C 15 s; 40 cycles were performed in total. Ribosomal 
protein L13a (RPL13A) was used as an endogenous control to 
calculate ∆∆ct. 
Polymerase chain reaction 
10 ng cDNA were amplified by PCR with specific primer pairs 
(1 µM each), and a master mix containing 14.875 µl RNAse-
free water, 2.5 µL 10-fold buffer, 0.5 µl 2' 
deoxyribonucleotides (dNTP) mix, and 0.125 µL Taq DNA 
polymerase (Taq PCR Core Kit, Qiagen). PCR was performed 
using PCR System 9700 cycler, 35 cycles and the following 
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cycler program: 94°C, 2 min; 94°C, 0.5 min; 58°C, 0.5 min; 
72°C, 0.5 min; 72°C, 10 min. PCR products were separated by 
gel electrophoresis in a 3 % agarose gel including 0.02 % 
ethidium bromide and Tris/Borate/EDTA buffer (TBE). Images 
were obtained using a digital camera. 
Sequences of oligonucleotides used for PCR and real-time PCR 
Xbp1unspliced: 5’-CAGACTACGTGCACCTCTGC-3’; 5’-
CTTCTGGGTAGACCTCTGGG-3', Xbp1 spliced: 5‘-
TCTGCTGAGTCCGCAGCAGG-3‘; 5’-CTTCTGGGTAGACCTCTGGG-
3', Xbp1u/s: 5’-CTGGAACAGCAAGTGGTAGA-3’; 5’-
CTGGGTCCTTCTGGGTAGAC-3’, BiP: 5’-
ACTATGAAGCCCGTCCAGAAAGT-3’; 5’-
TCGAGCCACCAACAAGAACA-3’ 
Statistical analyses 
One-way ANOVA with various post-test analyses were 
performed using GraphPad Prism version 5.04 software for 
Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com. The specific post-test and the number of 
donors are indicated in the figure legends. Significances are 
shown by asterisks, while P < 0.05, P < 0.01, and P < 0.001 are 
indicated by *, **, and ***, respectively. 
 
Results and Discussion 
Nanoparticle interaction with cells has to be analysed in detail 
for every unique nanoparticle. In this study, 20 nm PEGylated 
AuNPs are used. These were prepared by a standard ligand 
exchange process using thiolated PEG and citrate-stabilized 
gold particles.28 The resulting particles were characterized by 
dynamic light scattering (DLS) and UV / Vis spectroscopy (UV-
Vis), as shown in Supplemental figure 1. Upon functionalization 
with the PEG, the particle size increased slightly to 30 nm and 
displayed a small shift in the surface plasmon resonance band, 
indicative of a successful functionalization. The particles were 
also stable in various media, including PBS and cell culture 
media, thus confirming that the PEG coating stabilizes the 
particles and prevents non-specific adhesion of biomolecules. 
As a next step the nanoparticle suspension was analysed for a 
potential contamination with bacterial endotoxin to avoid the 
misinterpretation of cytokine release of endothelial cells 
following PEGylated AuNP treatment. As shown in 
Supplemental figure 2 none of the investigated PEGylated 
AuNP concentrations led to an upregulation of E-selectin in 
primary human endothelial cells compared to the untreated 
control. Thus, contamination with bacterial endotoxin could be 
excluded since this assay system was evaluated to be highly 
sensitive for the detection of endotoxin, as demonstrated by 
Unger et al..25 
After the characterization of the PEGylated AuNPs the impact 
of the nanoparticles on primary ECs (HUVEC) was determined. 
In Figure 1 A the results show that concentrations of PEGylated 
AuNPs up to 100 µg / mL were not toxic to HUVEC (as 
adjudged by the release of lactate dehydrogenase). In 
addition, the metabolic activity was not reduced in cells that 
were treated with a high dose of nanoparticles (Figure 1 B). 
These results were in agreement to previously published data 
by our group, which showed that 18 nm, 35 nm, and 65 nm 
PEGylated AuNPs were not toxic to human primary dermal 
microvascular endothelial cells or to brain microvascular 
endothelial cells.6,11 In addition, in vitro studies by other 
groups generally showed only a slight effect of PEGylated 
AuNPs on various cell types (alveolar type II cells, 
macrophages, microglia).29–31 However, the cell proliferation 
measured by the expression of the proliferation factor Ki-67 
was inhibited to 60 % when the cells were exposed to 
100 µg / mL PEGylated AuNPs for 24 hours (Figure 1 C). These 
data were supported by the determination of the cell number 
that was also reduced to 62 % compared to control cells under 
these conditions (Figure 1 D). 
 
Figure 1. Determination of cell biocompatibility of 20 nm PEGylated gold nanoparticles. 
HUVECs were treated with PEGylated AuNPs on cell culture dishes for 24 hours. (A) 
Cytotoxicity was determined by LDH-assay and data were normalized to lysed cells. (B) 
The MTS-Assay was used to determine cell viability and the acquired data were 
normalized to the untreated control expressed in %. (C) The proliferation was detected 
by measuring the proliferation factor Ki-67, while the cell number was determined 
using crystal violet staining (D). Results shown are means ± SD calculated using the 
results of at least three independent experiments. *: P < 0.05, **: P > 0.01; ***: P < 
0.001 compared to the appropriate untreated control (ONEway ANOVA with Dunnetts 
t-test; n = 2-7). (E, F) Merged images of HUVEC cultured on plastic dishes (E) and 
additionally treated with gold nanoparticles (F). Staining of CD31 (red) expressed in 
HUVEC, nuclei in blue and DIC, scale bars: 15 µm. 
The decreased proliferation rate after exposure to a high dose 
of PEGylated AuNPs is in agreement with the results observed 
in previous studies.27 Based on the cell viability determined in 
the various assays, NP concentrations of 12.5 to 25 µg / mL 
were used in further studies. The images presented in Figure 1 
E and F demonstrate that the exposure to 25µg / mL AuNPs 
did not affect the cell morphology of HUVEC and did not 
reduce or change the expression of CD31, a membrane-bound 
adhesion molecule, compared to the untreated control. These 
results demonstrated that PEGylated AuNPs applied to cells 
cultured under normal static cell culture conditions were not 
toxic and did not affect adhesion molecule expression by the 
cells. 
Contradictory results have been observed by He et al., who 
focused on the function of erythrocytes exposed to PEGylated 
AuNPs.14 They showed an unexpected reduction of oxygen-
delivering ability, a shortened lifetime of erythrocytes and a 
decreased expression of CD47 after AuNP exposure. Based on 
this, the potential impact of PEGylated AuNPs on endothelial 
cells was examined using more biologically relevant in vitro cell 
culture models to analyze the interaction of PEGylated AuNPs 
and endothelial cells under conditions closely mimicking the in 
vivo situation. 
Since it was shown that shear stress regulates EC function and 
differentiation,16,32 and enhanced the accumulation of 
liposomes targeted to vascular cell adhesion molecule- (VCAM-
) 1 and also non-targeted nanoparticles in endothelial cells,32,33 
nanoparticle-cell interactions were explored under 
physiological medium flow conditions. The cartoon in Figure 2 
A shows the movement of the added NPs across the cells 
under flow conditions. Cells were initially cultured for 48 hours 
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under flow, after which they were exposed to nanoparticles 
for a further 24 hours under flow conditions. 
 
Figure 2. Treatment of HUVEC with 20 nm PEGylated gold nanoparticles under flow 
culture conditions. 
(A) Cartoon of the flow culture model system (15 dyn / cm²). (B) Immunofluorescent 
images of HUVEC under flow culture conditions without (i) or exposed to gold 
nanoparticles (ii). Staining of CD31 (green) expressed in HUVEC, nuclei in blue, scale 
bars: 100 µm. (C) Quantification of internalized gold in HUVEC under static or flow 
culture conditions determined using ICP-OES (n = 6). 
The images in Figure 2 B i and ii show that the PEGylated 
AuNPs had no impact on the morphology of ECs. In addition, 
the amount of PEGylated AuNPs internalized by the cells was 
quantified using ICP-OES and compared to the uptake 
behaviour observed under static cell culture conditions (Figure 
2 C). Although the morphology of HUVECs changed after the 
application of shear stress (Supplemental figure 3), the 
internalization of PEGylated AuNPs was very low under both 
culture conditions (Figure 2 C). As PEGylation of nanoparticles 
was demonstrated to prolong the circulation time in blood 7,8 
and also delayed or even prevented the internalization into 
cells 6,34,35, the results of the flow experiments presented were 
in accordance with results previously described. In addition, 
the uptake of PEGylated AuNPs was very low; an altered 
internalization rate for the PEGylated AuNPs could be detected 
in cells cultured under static or flow conditions. This is also in 
agreement with the data previously published by Fede et al. 
who detected the same tendency for the internalization of 
AuNPs (w/o PEG) in HUVEC under static and flow conditions 
using a microfluidic system.36 
In addition to shear stress, cyclic stretch is also a prominent 
hemodynamic force which acts on endothelial cell function 
and membrane traffic17,37 and may alter the internalization of 
nanoparticles in endothelial cells. As previously reported, we 
showed that stretch affects the interaction of endothelial cells 
with amorphous silica nanoparticles and leads to a reduced 
internalization.19 In contrast, studies by Rouse et al. 
demonstrated an increased interaction of quantum dots with 
keratinocytes under stretch compared to static cell culture 
conditions.38 Thus, studies were carried out to determine if 
PEGylated AuNPs are internalized in different amounts in 
endothelial cells when cultured under stretch conditions  
 
Figure 3. Impact of 20 nm PEGylated AuNPs on HUVEC cultured under physiological 
stretch conditions. 
(A) Cartoon of the stretch model system (5 % stretch, 1 Hz). (B) Immunofluorescent 
images of HUVEC exposed to gold nanoparticles under static (i – iii) or stretch (iv – vi) 
culture conditions. Staining of CD31 (green) expressed in HUVEC (i + iv) and DIC images 
(ii + v); overlays in (iii) and (vi). Scale bars: 15 µm. (C) Secretion of interleukin-8 (IL-8), 
soluble vascular cell adhesion molecule (sVCAM), and monocyte chemoattractant 
protein-1 (MCP-1) after AuNP exposure under static (s) or stretch/flex (f) culture 
conditions measured by ELISA. LPS treatment was used as a positive control (n = 3-6). 
(D) PCR detecting spliced and unspliced Xbp1 mRNA via separation using a 3 % agarose 
gel. Actin was used as reference gene. (E) Quantitative real-time PCR for investigation 
of BiP, unspliced (Xbp1u) and spliced (Xbp1s) Xbp1 mRNA expression. Results are 
depicted as relative quantification (RQ) (n=2). (F) Quantification of BiP expression on 
protein level detected by Western Blot shown as X-fold change of static control (n=4). 
(G) Quantification of internalized gold in HUVEC under static or stretch culture 
conditions determined using ICP-OES (n=3). 
(Figure 3 A) and whether these culture conditions together 
with nanoparticles had any impact on cell function or 
morphology. In Figure 3 B the morphology of the cells after 
exposure to the nanoparticles under static (i – iii) and stretch 
(iv – vi) conditions is shown. Differences in the morphology 
could not be detected. Since agglomerates of internalized 
PEGylated AuNPs can also be detected by light microscopy,6 
the cells treated with AuNPs under both culture conditions 
were analysed using microscopy. However, no agglomerates of 
PEGylated AuNPs were visible within the cells (ii, v). In addition 
to the microscopic images, the quantification by ICP-OES 
indicated low levels of PEGylated AuNPs within the cells 
(Figure 3 G). In addition to the cellular uptake and changes in 
morphology the release of pro-inflammatory mediators after 
NP treatment in the stretch model system was examined. 
Based on the results previously reported by Santos-Martinez et 
al. that no induction of inflammatory response in endothelial 
cells after AuNP exposure was detectable, no release of 
cytokines by endothelial cells was expected in the stretch 
culture system.10 Moreover, Kim et al. could not identify any 
inflammation in the retina of C57BL/6 mice.39 Nevertheless, 
results from in vivo studies showed that inflammation of the 
liver after exposure to PEGylated AuNPs was present.13 Since 
endothelial cells are important for the homeostasis of tissues 
and organs and also play a crucial role in inflammation 
processes, the release of pro-inflammatory mediators after 
exposure to PEGylated AuNPs under the different culture 
conditions were analysed in the present in vitro study (Figure 3 
C). The results demonstrated that untreated control cells 
release a basic level of interleukin-8 (IL-8) under both culture 
conditions and that the level of IL-8 is slightly increased after 
the exposure to the NPs. However, no significant differences 
between the two culture conditions and the nanoparticle 
exposure in parallel were detected but the treatment with 
lipopolysaccharide (LPS) as positive control resulted in a 10-
fold increase of secretion of IL-8. These observations are 
mirrored by the secretion of monocyte chemoattractant 
protein-1 (MCP-1). Moreover, no soluble (s) VCAM was 
detected in the supernatant of untreated control cells and NP-
treated cells, either under static or under stretch culture 
conditions. In summary, no significant induction of 
inflammation processes were detected in ECs in the stretch 
model system compared to the LPS-treated endothelial cells. 
In addition to the analyses of the induction of pro-
inflammatory factors we also examined whether cell stress 
might occur in ECs after exposure to nanoparticles. Several 
studies have previously shown induced endoplasmic reticulum 
(ER) stress in different cell types after treatment with silver-
doped silica NPs,40 silver NPs41,42 or polystyrene 
nanospheres.43 Chen et al. showed that zinc oxide NPs 
triggered ER stress in HUVEC44 and gold NPs were shown to 
induce stress signaling in K562 cells.45 However, previous 
studies show that AuNPs of three different sizes and four 
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surface modifications did not cause any ER stress in brain 
endothelial cells.11 In general, ER stress is measurable by the 
detection of ER stress markers, which constitute components 
of the Unfolded Protein Response (UPR). Activating the 
signalling pathway UPR, the cells react on ER stress and begin 
to counteract the stress situation. In the event that a cell 
cannot restore homeostasis, apoptosis will be induced.46 Thus, 
activation of the UPR presents an early and sensitive marker 
for toxic potential of NPs. The expression of the UPR 
component chaperone BiP and splicing of xbp1 mRNA was 
determined in HUVEC under static and stretch cell culture 
conditions and in the presence or absence of the 
nanoparticles. Fig. 3 D shows the detection of unspliced and 
spliced form of xbp1 mRNA determined by PCR. Neither 
exposure of the cells to NP nor the different culture conditions 
led to splicing of xbp1 mRNA. In addition, real-time PCR studies 
examining xbp1 splicing demonstrated no differences between 
unspliced and the spliced form of the transcription factor 
mRNA (Fig. 3 E). Furthermore, expression of BiP at the mRNA 
level was not increased after NP treatment. A slight increase of 
BiP, xbp1u and xbp1s mRNA was detected under stretch 
culture conditions. However, these changes were neither 
numerically large nor statistically significant. In addition, we 
investigated the expression of the ER stress marker BiP at the 
protein level by Western Blot analysis. Quantification of BiP 
expression (Fig. 3 F) showed a minor but non-significant 
decrease of BiP expression as a result of PEGylated AuNP 
treatment. Changes in expression due to static and stretch 
culture conditions were not observed. In summary, treatment 
with PEGylated AuNPs did not lead to ER stress and UPR 
activation in HUVEC under static, as well as stretch culture 
conditions. This kind of stress resistance of HUVEC to AgNPs 
has been previously described by Huo et al..42 
In addition to the hemodynamic forces that alter the 
phenotype of endothelial cells and may also effect 
nanoparticle-cell interactions, whether the barrier function of 
endothelial cells is influenced during nanoparticle exposure is 
also of great importance. In particular, capillary endothelial 
cells in the brain form a very tight barrier which protects the 
brain from endobiotic and xenobiotic substances.23 In order to 
examine this, a well-characterized blood-brain barrier model 
was used to determine whether the barrier function is 
influenced during exposure to PEGylated AuNPs (Figure 4 
A).20,21 
 
Figure 4. Assessment of the impact of 20 nm PEGylated AuNPs on endothelial cells 
forming the blood-brain barrier. 
(A) Cartoon of the blood-brain barrier co-culture model. (B) The MTS-Assay was used to 
determine cell viability after 24 hours of exposure to PEGylated AuNPs and the 
acquired data were normalized to the untreated control expressed in % (n = 3 - 4). (C) 
Immunofluorescence staining of claudin-5 proteins (green) expressed in PBEC without 
PEGylated AuNPs (i) or after PEGylated AuNPs treatment (ii). Nuclei in blue, scale bars: 
200 µm. (D) Transendothelial electrical resistance (TEER) was measured before and 
after the exposure to gold nanoparticles for 24 hours. Ctrl was treated with the 
corresponding volume of diluent. Data represent the mean ± standard deviation of four 
experiments. Cells with at least 170 Ohm x cm² were used (n = 4 - 5). (E) To ensure the 
tightness of the barrier during the treatment with PEGylated AuNPs, the permeability 
coefficient of sodium fluorescein was simultaneously determined (n = 2). (F) 
Quantification of transported gold across the PBEC barrier using ICP-OES (n = 3). (G) 
Secretion of interleukin-8 from PBECs during PEGylated AuNP treatment was compared 
to the untreated control (n = 2 - 6). 
The blood-brain barrier model was exposed to nanoparticle 
(12.5 µg / mL and 25 µg / mL) to evaluate the impact on the 
metabolism of brain endothelial cells. The results of the 
viability assay shown in Figure 4 B demonstrate that exposure 
to the two concentrations of NP had no impact on the primary 
porcine brain microvascular endothelial cells (PBECs). Also, no 
changes to the cell morphology or to cell-cell contacts were 
observed during exposure to PEGylated AuNPs. This was 
shown by the staining of the tight junction protein claudin-5 
(Figure 4 C). Moreover, the levels of the transendothelial 
electrical resistance (TEER) demonstrated that the tight 
junctions were not affected by NP exposure (Figure 4 D). The 
integrity of the barrier was also determined based on the 
permeability of the model substance sodium fluorescein. The 
permeability coefficient of untreated and NP-exposed cells 
was determined and compared (Figure 4 E). No differences 
were observed in the permeability coefficient between NP-
exposed and control cells. Thus, based on the results obtained 
by the measurement of the TEER and the sodium fluorescein 
permeability results we can conclude that the barrier function 
of the endothelial cells was not altered when exposed to the 
20 nm PEGylated AuNPs. The amount of PEGylated AuNPs 
transported across the endothelial cell layer was also 
determined. The ICP-OES data illustrated in Figure 4 F show 
that the AuNPs were not transported across the cell barrier. In 
addition, the PEGylated NPs did not induce any inflammatory 
response in the PBECs even at a dose of 25 µg / mL PEGylated 
AuNPs (Figure 4 G). Recently published data by the Trickler 
group also demonstrated that PBEC did not secrete 
inflammatory mediators in response to exposure to 5 nm 
AuNPs.47 This group also showed no changes in barrier 
integrity, the absence of cytotoxicity and no induction of 
inflammatory cytokines in rat brain microvascular endothelial 
cells exposed to the 5 nm AuNPs, similar to the results 
observed in the present studies with porcine brain endothelial 
cells and the 20 nm PEGylated AuNPs.48 
Taken together, the results of this study indicate that 
PEGylated gold nanoparticles did not impact peripheral 
endothelial cells evaluated in two physiological hemodynamic 
model systems. Moreover, the healthy blood-brain barrier is 
not affected by PEGylated AuNPs. In contrast Etame et al. 
previously showed by using a transport-permissive brain 
microvasculature model system that optimizing the size of 
AuNPs and the length of the PEG chain results in a transport of 
AuNPs across the brain microvasculature. They proposed that 
such modified AuNPs might be transported across the barrier 
into the brain tissue or possibly into malignant brain tumors.49 
In addition, it has been shown that the application of 
PEGylated AuNPs resulted in a significant decrease in cancer 
cell survival after gamma radiation in vitro and that AuNPs 
accumulated in high concentrations in tumors while also 
decreasing tumor volume in vivo.50 These results ultimately 
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lead to the conclusion that PEGylated AuNPs might be useful 
as nanotools for improved radiotherapy while not affecting 
peripheral and healthy brain endothelial cells or the integrity 
of the BBB. 
Nevertheless, previous studies have also demonstrated that 
AuNPs have an impact on both liver and kidney in mice,13 
indicating that these NPs need to be carefully evaluated prior 
to future medical applications. However, PEGylated AuNPs 
have a number of positive properties as demonstrated by 
several studies. Modifying the surface of the NPs with an 
additional targeting protein/sequence may reduce the side 
effects causing liver impairment. However, each uniquely-
modified AuNP needs to be evaluated prior to use in medical 
applications. Thus, by using the more complex in vitro models 
described in the present study which mimic the in vivo 
situation, a more biologically relevant evaluation of novel NPs 
can be obtained and the most effective NPs can be selected for 
further animal studies. However, even though these model 
systems lead to a more physiological phenotype of endothelial 
cells, the models cannot completely replace in vivo studies. 
Additional comparative studies between these models with 
animal studies will be necessary to determine whether the 
more complex in vitro models truly mimic what is observed in 
vivo. Beside the hemodynamic forces, the clearance of 
nanoparticles by blood cells, the liver, spleen and kidney 
cannot totally be investigated in in vitro experiments and must 
also be determined. Thus, as stated by Shah and Bischof, in 
vitro experiments are efficient for screening processes but in 
vivo studies are also necessary for confirming the in vitro data, 
especially for blood-nanoparticle interactions.51 
Conclusions 
Cell culture models which more closely reproduce the in vivo 
environment were used to investigate the effects of 20 nm 
PEGylated AuNPs on endothelial cells (ECs). These culture 
conditions represent a position between traditional static 
culture methods and in vivo studies by mimicking the stretch 
and shear-stress that ECs undergo continuously in vivo. ECs 
under these conditions were evaluated using a large panel of 
assays to probe cellular stress and function. We observed that 
cells cultured under flow as well as under stretch condition 
were not affected by the PEGylated AuNPs. No impact on cell 
morphology, cell viability and no induction of inflammatory or 
unfolded protein responses (UPR) caused by endoplasmic 
stress was shown. Even the barrier properties of brain 
microvascular ECs were affected by the treatment with the 20 
nm PEGylated AuNPs. Internalization of the PEGylated AuNPs 
did not differ significantly between static and flow or stretch 
condition. In addition the transport across the brain ECs was 
very low. These more physiological model systems 
demonstrated that PEGylated AuNPs have many cell-
favourable attributes and may be used as a basis in developing 
a new generation of nanoparticles for medical applications. 
Moreover, the results from the EC-culture models 
demonstrate in vivo-like characteristics and these models 
could be a useful addition between traditional static in vitro 
culture studies and in vivo toxicity and efficacy studies. As a 
consequence using these models for NP evaluation studies 
could reduce animal experiments and drug developmental 
costs. 
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Figure 1. Determination of cell biocompatibility of PEGylated gold nanoparticles.  
HUVECs were treated with PEGylated AuNPs on cell culture dishes for 24 hours. (A) Cytotoxicity was 
determined by LDH-assay and data were normalized to lysed cells. (B) The MTS-Assay was used to 
determine cell viability and the acquired data were normalized to the untreated control expressed in %. (C) 
The proliferation was detected by measuring the proliferation factor Ki-67, while the cell number was 
determined using crystal violet staining (D). Results shown are means ± SD calculated using the results of 
at least three independent experiments. *: P < 0.05, **: P > 0.01; ***: P < 0.001 compared to the 
appropriate untreated control (ONEway ANOVA with Dunnetts t-test; n = 2-7). (E, F) Merged images of 
HUVEC cultured on plastic dishes (E) and additionally treated with gold nanoparticles (F). Staining of CD31 
(red) expressed in HUVEC, nuclei in blue and DIC, scale bars: 15 µm.  
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Figure 2. Treatment of HUVEC with 20 nm PEGylated gold nanoparticles under flow culture conditions.  
(A) Cartoon of the flow culture model system (15 dyn / cm²). (B) Immunofluorescent images of HUVEC 
under flow culture conditions without (i) or exposed to gold nanoparticles (ii). Staining of CD31 (green) 
expressed in HUVEC, nuclei in blue, scale bars: 100 µm. (C) Quantification of internalized gold in HUVEC 
under static or flow culture conditions determined using ICP-OES (n = 6).  
 
85x42mm (300 x 300 DPI)  
 
 
Page 10 of 13Biomaterials Science
  
 
 
Figure 3. Impact of PEGylated AuNPs on HUVEC cultured under physiological stretch conditions.  
(A) Cartoon of the stretch model system (5 % cyclic stretch, 1 Hz). (B) Immunofluorescent images of 
HUVEC exposed to gold nanoparticles under static (i – iii) or stretch (iv – vi) culture conditions. Staining of 
CD31 (green) expressed in HUVEC (i + iv) and DIC images (ii + v); overlays in (iii) and (vi). Scale bars: 15 
µm. (C) Secretion of interleukin-8 (IL-8), soluble vascular cell adhesion molecule (sVCAM), and monocyte 
chemoattractant protein-1 (MCP-1) after AuNP exposure under static (s) or stretch/flex (f) culture conditions 
measured by ELISA. LPS treatment was used as a positive control (n = 3-6). (D) PCR detecting spliced and 
unspliced Xbp1 mRNA via separation using a 3 % agarose gel. Actin was used as reference gene. (E) 
Quantitative real-time PCR for investigation of BiP, unspliced (Xbp1u) and spliced (Xbp1s) Xbp1 mRNA 
expression. Results are depicted as relative quantification (RQ) (n=2). (F) Quantification of BiP expression 
on protein level detected by Western Blot shown as X-fold change of static control (n=4). (G) Quantification 
of internalized gold in HUVEC under static or stretch culture conditions determined using ICP-OES (n=3).  
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Figure 4. Assessment of the impact of 20 nm PEGylated AuNPs on endothelial cells forming the blood-brain 
barrier.  
(A) Cartoon of the blood-brain barrier co-culture model. (B) The MTS-Assay was used to determine cell 
viability after 24 hours of exposure to PEGylated AuNPs and the acquired data were normalized to the 
untreated control expressed in % (n = 3 - 4). (C) Immunofluorescence staining of claudin-5 proteins (green) 
expressed in PBEC without PEGylated AuNPs (i) or after PEGylated AuNPs treatment (ii). Nuclei in blue, scale 
bars: 200 µm. (D) Transendothelial electrical resistance (TEER) was measured before and after the exposure 
to gold nanoparticles for 24 hours. Ctrl was treated with the corresponding volume of diluent. Data 
represent the mean ± standard deviation of four experiments. Cells with at least 170 Ohm x cm² were used 
(n = 4 - 5). (E) To ensure the tightness of the barrier during the treatment with PEGylated AuNPs, the 
permeability coefficient of sodium fluorescein was simultaneously determined (n = 2). (F) Quantification of 
transported gold across the PBEC barrier using ICP-OES (n = 3). (G) Secretion of interleukin-8 from PBECs 
during PEGylated AuNP treatment was compared to the untreated control (n = 2 - 6).  
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 The use of physiological cell cultures as screening platforms helps to determine potential 
nanomaterial toxicity prior to in vivo experiments. 
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